MYOMO INC. NEW DL-,0001 Logo
US62857J2015
A2PZCL
MYO

MYOMO INC. NEW DL-,0001

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 0,95 € (-31,16%). La mediana è 0,95 € (-31,16%).

Acquista
  7
Mantieni
  1
Vendi
  0

  • Myomo raises 2026 revenue guidance after Q2 revenue grows 21%

    Myomo reported Q2 revenue of $11.7 million, up 21% year over year, driven by a 19% increase in recognized MyoPro units to 211 and a record 255 orders. Recurring referral sources now account for 53% of quarterly revenue (vs. 26% a year earlier) as the company expands its referral network above 300 sites. Gross margin improved to 72.1% and operating loss narrowed to $2.3 million; adjusted EBITDA loss fell to $800,000. Management raised full-year 2026 revenue guidance to $45 million–$47 million, expects Q3 revenue of $11.5 million–$12 million, and forecasts second-half cash burn below $2 million. » Altro su finance.yahoo.com


  • Myomo beats Q2 expectations and raises revenue guidance

    Myomo reported a 21% rise in Q2 revenue to $11.7 million, a reduced net loss of $0.09 per share and a markedly improved gross margin of 72.1%. The quarter was supported by a record order intake of 255 MyoPro units and 211 devices delivered. The company raised its 2026 revenue guidance to $45–47 million and signaled progress on operating leverage. The stock rose modestly in after-hours trading following the results. » Altro su de.investing.com


  • Myomo beats Q1 forecasts, stock falls after-hours

    Myomo reported better-than-expected Q1 results: EPS -$0.07 (expected -$0.12) and revenue $10.1 million (expected $9.24 million). Revenue rose 3% year-on-year, gross margin improved to 68.2%, and the company shipped 172 MyoPro units. For Q2 Myomo forecasts revenue between $10.3 million and $10.8 million; nevertheless the stock fell after-hours, initially by 2.98% and then declined further. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, MYOMO INC. NEW DL-,0001 ha registrato ricavi pari a 10,26 Mln € e un utile netto di -3,52 Mln €
(EUR) giu 2026
YoY
Ricavi 10,26 Mln 25,23%
Utile lordo 7,4 Mln 44,07%
Utile netto -3,52 Mln 10,34%
EBITDA -3,03 Mln 12,03%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
53,37 Mln €
Numero di azioni
38,64 Mln
Massimo/minimo a 52 settimane
1,63 € - 0,52 €
Dividendi No
Beta
1,44
Rapporto P/E
-4,70
Rapporto PEG
0,11
Rapporto P/B
11,72
Rapporto P/S
1,43

Profilo aziendale

Myomo, Inc. ist ein Unternehmen für tragbare medizinische Robotik und entwirft, entwickelt und produziert myoelektrische Orthesen für Menschen mit neuromuskulären Störungen in den Vereinigten Staaten. Das Unternehmen bietet MyoPro an, eine myoelektrisch gesteuerte Orthese für die oberen Gliedmaßen, die zur Unterstützung des schwachen oder gelähmten Arms eines Patienten verwendet wird, um funktionelle Aktivitäten des täglichen Lebens zu ermöglichen und zu verbessern. Die Produkte des Unternehmens wurden entwickelt, um die Funktion von Erwachsenen und Jugendlichen mit neuromuskulären Erkrankungen aufgrund von Verletzungen des Plexus brachialis, Schlaganfall, Schädel-Hirn-Trauma, Rückenmarksverletzungen und anderen neurologischen Erkrankungen zu verbessern. Das Unternehmen verkauft seine Produkte an Anbieter von Orthesen und Prothesen, die Veterans Health Administration und Rehabilitationskliniken sowie über Vertriebshändler. Myomo, Inc. wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.

Nome
MYOMO INC. NEW DL-,0001
CEO
Paul R. Gudonis
Sede centrale Burlington, ma
Stati Uniti
Sito web
Settore
Industria
Industria
Servizi e forniture commerciali
Quotazione in borsa
12/06/2017
Dipendenti 195

Simboli di borsa

Borsa Simbolo
AMEX
MYO
Frankfurt
0M61.F
Düsseldorf
0M61.DU

Scopri gli asset

Gli azionisti di MYOMO INC. NEW DL-,0001 investono anche nei seguenti asset

🍪

Parqet  usa i cookie. Scopri di più